OBJECTIVE: The objective of this study was to assess patients' preferences of the timing of referral for genetic counseling and testing in relation to the diagnosis, treatment, and recurrence of ovarian, tubal, or primary peritoneal cancers. METHODS: Ninety-two patients who underwent counseling and testing by 1 certified genetic counselor were identified. An introductory letter, consent form, and questionnaire were mailed to gather information regarding factors influencing the decision to undergo genetic counseling and testing and opinions regarding optimal timing. Medical records were reviewed for demographic and clinical data. RESULTS: Of 47 consenting women, 45 underwent testing. Eight (18%) were found to have a genetic mutation. Women lacked consensus about the optimal time for referral for and to undergo genetic testing, although women with stage I disease preferred testing after completion of chemotherapy. Most women were comfortable receiving the results by phone, but one third preferred an office visit. CONCLUSIONS: Patients' views regarding the best time to be referred for and undergo counseling and testing varied greatly. Because of the high mortality of this disease, clinicians should discuss referral early and personalize the timing to each patient. The subset of patients who prefer results disclosure during an office visit should be identified at the time of their initial counseling.
OBJECTIVE: The objective of this study was to assess patients' preferences of the timing of referral for genetic counseling and testing in relation to the diagnosis, treatment, and recurrence of ovarian, tubal, or primary peritoneal cancers. METHODS: Ninety-two patients who underwent counseling and testing by 1 certified genetic counselor were identified. An introductory letter, consent form, and questionnaire were mailed to gather information regarding factors influencing the decision to undergo genetic counseling and testing and opinions regarding optimal timing. Medical records were reviewed for demographic and clinical data. RESULTS: Of 47 consenting women, 45 underwent testing. Eight (18%) were found to have a genetic mutation. Women lacked consensus about the optimal time for referral for and to undergo genetic testing, although women with stage I disease preferred testing after completion of chemotherapy. Most women were comfortable receiving the results by phone, but one third preferred an office visit. CONCLUSIONS:Patients' views regarding the best time to be referred for and undergo counseling and testing varied greatly. Because of the high mortality of this disease, clinicians should discuss referral early and personalize the timing to each patient. The subset of patients who prefer results disclosure during an office visit should be identified at the time of their initial counseling.
Authors: Tamar Safra; Lucia Borgato; Maria Ornella Nicoletto; Linda Rolnitzky; Sharon Pelles-Avraham; Ravit Geva; Martin Edward Donach; John Curtin; Akiva Novetsky; Tal Grenader; Wei-Chu V Lai; Alberto Gabizon; Leslie Boyd; Franco Muggia Journal: Mol Cancer Ther Date: 2011-08-11 Impact factor: 6.261
Authors: J Boyd; Y Sonoda; M G Federici; F Bogomolniy; E Rhei; D L Maresco; P E Saigo; L A Almadrones; R R Barakat; C L Brown; D S Chi; J P Curtin; E A Poynor; W J Hoskins Journal: JAMA Date: 2000-05-03 Impact factor: 56.272
Authors: B Meiser; M Gleeson; N Kasparian; K Barlow-Stewart; M Ryan; K Watts; D Menon; G Mitchell; K Tucker Journal: Gynecol Oncol Date: 2011-10-26 Impact factor: 5.482
Authors: Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra Journal: J Clin Oncol Date: 2010-06-14 Impact factor: 44.544
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Marijke R Wevers; Daniela E E Hahn; Senno Verhoef; Marijke D K Bolhaar; Margreet G E M Ausems; Neil K Aaronson; Eveline M A Bleiker Journal: Patient Educ Couns Date: 2012-04-28
Authors: S A Smith; D F Easton; D Ford; J Peto; K Anderson; D Averill; M Stratton; M Ponder; C Pye; B A Ponder Journal: Am J Hum Genet Date: 1993-04 Impact factor: 11.025
Authors: Sue V Petzel; Rachel Isaksson Vogel; Jena McNiel; Anna Leininger; Peter A Argenta; Melissa A Geller Journal: Int J Gynecol Cancer Date: 2014-07 Impact factor: 3.437
Authors: Jude Emmanuel Cléophat; Michel Dorval; Zaki El Haffaf; Jocelyne Chiquette; Stephanie Collins; Benjamin Malo; Vincent Fradet; Yann Joly; Hermann Nabi Journal: BMC Med Genomics Date: 2021-06-26 Impact factor: 3.063